Skip to Content
381

AbbVie

  • Previous Rank422
  • Country
    U.S.
  • Revenues ($M)$32,753.00
  • Revenue Percent Change16.1%
  • Profits ($M)$5,687.00
  • Profits Percent Change7.1%
  • Assets ($M)$59,352.00
  • Employees30,000

AbbVie—a North Chicago, Ill.-based biopharmaceutical company—is laying the foundation for its future as the company looks to move beyond its flagship drug Humira. Global Humira sales dropped 5.6% to $4.4 billion in the first quarter of 2019. The drug took a steep 27.9% downturn in international markets during the same time period in part due to the entry of biosimilars in Europe. This contrasts with global Humira sales in FY2018, which increased 8.2% year-over-year to $19.9 billion. Still, AbbVie raised its earnings-per-share guidance for 2019 in April coming off the FDA approval of its drug Skyrizi. The plaque psoriasis drug has been reported to be set to launch later this year.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

CEO
Richard A. Gonzalez
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
North Chicago, Ill.
Websitehttps://www.abbvie.com
Years on Global 500 List4
Employees30,000

AbbVie Rank History

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$32,753.0016.1%
Profits ($M)$5,687.007.1%
Assets ($M)$59,352.00-
Total Stockholder Equity ($M)$-8,446.00-

Profit Ratios

Profit as % of Revenues17.4%
Profits as % of Assets9.6%
Profits as % of Stockholder Equity-